EMA Authorised: Capvaxive (pneumococcal polysaccharide serotype 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B de-O-acetylated, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F and 35B conjugated to CRM197 carrier protein) — Merck Sharp & Dohme B.V.

View source ↗

Summary

EMA has authorised Capvaxive, a pneumococcal conjugate vaccine covering multiple serotypes and developed by Merck Sharp & Dohme B.V., for prevention of pneumoco…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• Capvaxive

Snippet

Status: Authorised. Therapeutic area: Pneumococcal Infections. MAH: Merck Sharp & Dohme B.V.. Decision date: 06/10/2025